Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both MRNA Therapeutic Programs On Track For First Half Of 2025
Arcturus Therapeutics Announces Initiation Of Dosing In Phase 2 Multiple Ascending Dose Studies For Cystic Fibrosis And Ornithine Transcarbamylase Deficiency; Phase 2 Interim Data For Both MRNA Therapeutic Programs On Track For First Half Of 2025
Each participant in the Phase 2 CF study (NCT06747858) is expected to receive daily treatments of ARCT-032 over a period of 28 days.First participants initiated Phase 2 dosing for both CF and OTC deficiency in December 2024
首批参与者于2024年12月启动了CF和场外交易缺乏症的第二阶段给药。
Phase 2 interim data for both mRNA therapeutic programs on track for first half of 2025
针对两种mRNA治疗方案的第二阶段临时数据预计在2025年上半年公布。
Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first CF and OTC deficiency participants initiated dosing in December 2024, in the Company's Phase 2 multiple ascending dose studies.
Arcturus Therapeutics Holdings Inc.（"公司"，"Arcturus"，纳斯达克：ARCT）是一家专注于开发传染病疫苗及肝脏和呼吸罕见疾病机遇的商业信使RNA药物公司，今天宣布首批CF和场外交易缺乏症参与者于2024年12月在公司第二阶段多次递增剂量研究中启动给药。
Each participant in the Phase 2 CF study (NCT06747858) is expected to receive daily treatments of ARCT-032 over a period of 28 days.
预计第二阶段CF研究（NCT06747858）中的每位参与者将在28天内接受ARCt-032的每日治疗。
The first OTC deficient participant receiving 0.5 mg/kg ARCT-810 initiated dosing in December 2024 in the United States. Each participant is expected to receive five intravenous infusions administered over two months. The Company previously announced the completion of the dosing phase (N = 8; 0.3 mg/kg) in a placebo-controlled European study enrolling OTC deficient individuals and expansion of the Phase 2 clinical program of ARCT-810 into the United States with an open-label multiple-dose study (NCT06488313).
首位0.5 mg/kg ARCt-810的场外交易缺乏症参与者于2024年12月在美国启动给药。预计每位参与者将在两个月内接受五次静脉注射。公司之前宣布在一项对照安慰剂的欧洲研究中完成了给药阶段（N = 8；0.3 mg/kg），该研究招募了场外交易缺乏症个体，并扩展了ARCt-810第二阶段临床计划至美国，进行开放标签的多剂量研究（NCT06488313）。
